NASDAQ:QURE

Uniqure N.v Stock Insider Trading

Healthcare > Biotechnology

Buy QURE

*Your capital is at risk

$29.88

+3.12 (+11.66%)

At Close: Jun 03, 2026

uniQure N.V Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -83.37. In total, the insiders bought 1.97M and sold 786.77K QURE shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-83.37
● Buy	1.97M shares
● Sell	786.77K shares
47% Buy Activity Moderate Negative Correlation
Buy Signal Low Confidence Mar 04, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -83.37. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 25, 2026 Sell	Ordinary Shares S-Sale	Klemt Christian Chief Financial Officer	C-Suite Officer	6 217 Value: $148.3K
Jan 12, 2026 Buy	Ordinary Shares M-Exempt	Gut Robert Director	Director	17 810 Value: $250.8K
Jan 12, 2026 Sell	Ordinary Shares S-Sale	Gut Robert Director	Director	17 310 Value: $422.2K
Jan 12, 2026 Sell	Ordinary Shares S-Sale	Gut Robert Director	Director	500 Value: $12.5K
Jan 12, 2026 Sell	Ordinary Shares S-Sale	Gut Robert Director	Director	7 803 Value: $195.8K
Jan 12, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Gut Robert Director	Director	17 810 Value: $250.8K
Jan 09, 2026 Buy	Ordinary Shares M-Exempt	Kaye Jack Director	Director	6 390 Value: $123.9K
Jan 09, 2026 Sell	Ordinary Shares S-Sale	Kaye Jack Director	Director	6 390 Value: $174.3K
Jan 09, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Kaye Jack Director	Director	6 390 Value: $123.9K
Nov 06, 2025 Sell	Ordinary Shares S-Sale	Gut Robert Director	Director	15 594 Value: $425.7K
Nov 06, 2025 Sell	Ordinary Shares S-Sale	Gut Robert Director	Director	15 840 Value: $431.2K
Nov 06, 2025 Buy	Ordinary Shares M-Exempt	Gut Robert Director	Director	15 840 Value: $72.4K
Nov 06, 2025 Buy	Stock Option (Right to Buy) M-Exempt	Gut Robert Director	Director	15 840 Value: $72.4K
Nov 04, 2025 Buy	Stock Option (Right to Buy) M-Exempt	Kaye Jack Director	Director	11 000 Value: $59.1K
Nov 04, 2025 Buy	Stock Option (Right to Buy) M-Exempt	Kaye Jack Director	Director	10 000 Value: $73.7K
Nov 04, 2025 Buy	Stock Option (Right to Buy) M-Exempt	Kaye Jack Director	Director	17 810 Value: $250.8K
Nov 04, 2025 Sell	Ordinary Shares S-Sale	Kaye Jack Director	Director	17 810 Value: $540.2K
Nov 04, 2025 Sell	Ordinary Shares S-Sale	Kaye Jack Director	Director	11 000 Value: $333.7K
Nov 04, 2025 Sell	Ordinary Shares S-Sale	Kaye Jack Director	Director	10 000 Value: $303.6K
Nov 04, 2025 Buy	Ordinary Shares M-Exempt	Kaye Jack Director	Director	10 000 Value: $73.7K
Nov 04, 2025 Buy	Ordinary Shares M-Exempt	Kaye Jack Director	Director	11 000 Value: $59.1K
Nov 04, 2025 Buy	Ordinary Shares M-Exempt	Kaye Jack Director	Director	17 810 Value: $250.8K
Sep 26, 2025 Buy	Ordinary Shares M-Exempt	Klemt Christian Chief Financial Officer	C-Suite Officer	15 000 Value: $80.6K
Sep 26, 2025 Sell	Ordinary Shares S-Sale	Klemt Christian Chief Financial Officer	C-Suite Officer	15 000 Value: $825.0K
Sep 26, 2025 Buy	Stock Option (Right to Buy) M-Exempt	Klemt Christian Chief Financial Officer	C-Suite Officer	15 000 Value: $80.6K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT UNIQURE N.V.

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phas...

Read Full Profile Here